Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
20. Mai 2023 08:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Announces First Quarter 2023 Results and Pipeline Updates
09. Mai 2023 16:05 ET
|
Senti Biosciences, Inc.
– New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 – – Initial collaboration...
Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting
02. Mai 2023 16:45 ET
|
Senti Biosciences, Inc.
- Four abstracts accepted show the potential of applying gene circuits in multiple cell and gene therapy modalities for neurology, ophthalmology, and oncology - - New preclinical data demonstrate...
Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting
17. April 2023 08:45 ET
|
Senti Biosciences, Inc.
– Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission in 2H 2023 – – Additional data presented on SENTI-301A...
Senti Bio to Participate in Upcoming Investor Conferences
14. April 2023 09:00 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
22. März 2023 17:09 ET
|
Senti Biosciences, Inc.
- SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS - -...
Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting
14. März 2023 16:35 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Biosciences Announces New Employment Inducement Grants
03. Februar 2023 16:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio to Present at the SVB Securities Global Biopharma Conference
01. Februar 2023 16:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
27. Januar 2023 08:00 ET
|
Senti Biosciences, Inc.
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other...